{"id":30451,"date":"2022-06-09T17:43:07","date_gmt":"2022-06-09T15:43:07","guid":{"rendered":"https:\/\/www.transgene.com\/?p=30451"},"modified":"2024-11-08T10:36:52","modified_gmt":"2024-11-08T09:36:52","slug":"annonce-tg4050","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/annonce-tg4050\/","title":{"rendered":"annonce TG4050"},"content":{"rendered":"\n\n\n<div class=\"wp-block-columns eplus-SbjXLy eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-kLEoHv eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div id=\"annonceHome\" class=\"wp-block-columns alignfull eplus-1ruALO\">\n<div id=\"therapeuticvaccines\" class=\"wp-block-column eplus-17Ffl8 bandeau\">\n<div>\n<h1 style=\"text-align: center; color: #ffffff;\">Preuve de principe clinique<br>dans les cancers de la t\u00eate et du cou <br>\n<\/h1>\n<div class=\"OAM-arrow\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-28928 size-full aligncenter\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/arrowDown.gif\" alt=\"\" width=\"250\" height=\"200\"><\/div>\n<\/div>\n<div id=\"annonce-lien\">\n    <h2 style=\"color:#c544d0;\">Tous les patients trait\u00e9s sont en r\u00e9mission apr\u00e8s une m\u00e9diane de suivi de 24,1 mois        <br\/><\/h2><p> &nbsp;<\/p>\n<p style=\"text-align: center; color: white;\"><a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241107_TG4050_PosterSITC2024_FR.pdf\" target=\"_blank\" rel=\"noopener\">Communiqu\u00e9 [PDF]<\/a><\/p>\n<p style=\"text-align: center; color: white;\"><a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20241108_TG4050_SITC2024_Poster.pdf\" target=\"_blank\" rel=\"noopener\">Poster pr\u00e9sent\u00e9 au SITC 2024\u00a0<\/a><\/p>\n\n\n<div id=\"moreCache\"><p style=\"text-align: center; color: white;\"><a style=\"color:#a4b0f9;\" href=\"https:\/\/player.vimeo.com\/video\/932496784\" target=\"_blank\" rel=\"noopener\" data-wplink-url-error=\"true\">Listen to Dr. Alessandro Riva\u2019s comments, Chairman &#038; CEO of Transgene (VOST)\n<\/a><\/p>\n<p style=\"text-align: center; color: white;\"><a style=\"color:#a4b0f9;\" id=\"618at\" class=\"lienHome\" title=\"\" href=\"https:\/\/player.vimeo.com\/video\/932496724\">Liste to the KOL Event TG4050 (April, 2023) (in English) <\/a><\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns eplus-LGzveY cgProduct eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-eypt3I eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<h2>Un patient, un cancer, un vaccin<\/h2>\n<h3 class=\"cgDeg2\"><b>Avec TG4050, Transgene d\u00e9veloppe une immunoth\u00e9rapie individualis\u00e9e issue de technologies avanc\u00e9es d\u2019ing\u00e9nierie g\u00e9n\u00e9tique et d\u2019intelligence artificielle (IA). <br><\/b>Le traitement repose sur un vecteur viral optimis\u00e9, le&nbsp;MVA.<\/h3>\n\n\n\n<p>&nbsp;<\/p>\n<p><a class=\"btnVideo cgProductVideo\" title=\"\" href=\"https:\/\/vimeo.com\/481155014?width=640&amp;height=480\" rel=\"wp-video-lightbox\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-27522\" src=\"..\/..\/..\/wp-content\/uploads\/btn-video.svg\" alt=\"\" width=\"101\" height=\"63\"> &nbsp;<em>myvac<\/em>\u00ae video<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column eplus-VVuil8 eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<p>Chaque traitement est con\u00e7u et fabriqu\u00e9 par Transgene, sur mesure, pour chaque patient, en visant les cibles tumorales les plus pertinentes (n\u00e9oantig\u00e8nes propres \u00e0 chaque cancer) s\u00e9lectionn\u00e9es par l\u2019IA de NEC.<\/p>\n<p>Un fois inject\u00e9 au malade, ce vaccin th\u00e9rapeutique va stimuler les d\u00e9fenses immunitaires du patient pour permettre une destruction cibl\u00e9e des cellules canc\u00e9reuses.<\/p>\n<p><b>Pour mener \u00e0 bien ce projet, Transgene s\u2019appuie sur une expertise unique, un r\u00e9seau de partenaires prestigieux et reconnus \u00e0 chaque \u00e9tape de la conception du produit et des capacit\u00e9s manufacturi\u00e8res int\u00e9gr\u00e9es. <\/b><\/p>\n<figure class=\"wp-block-image size-full eplus-YPnM8s\"><img decoding=\"async\" class=\"wp-image-27869\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/process.svg\" alt=\"\" \/><\/figure>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preuve de principe cliniquedans les cancers de la t\u00eate et du cou Tous les patients trait\u00e9s sont en r\u00e9mission apr\u00e8s une m\u00e9diane de suivi de 24,1 mois &nbsp; Communiqu\u00e9 [PDF] Poster pr\u00e9sent\u00e9 au SITC 2024\u00a0 Listen to Dr. Alessandro Riva\u2019s comments, Chairman &#038; CEO of Transgene (VOST) Liste to the KOL Event TG4050 (April, 2023)&hellip; <a class=\"more-link\" href=\"https:\/\/www.transgene.com\/fr\/annonce-tg4050\/\">Poursuivre la lecture <span class=\"screen-reader-text\">annonce TG4050<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[110],"tags":[],"class_list":["post-30451","post","type-post","status-publish","format-standard","hentry","category-outils-produits","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"Preuve de principe cliniquedans les cancers de la t\u00eate et du cou Tous les patients trait\u00e9s sont en r\u00e9mission apr\u00e8s une m\u00e9diane de suivi de 24,1 mois &nbsp; Communiqu\u00e9 [PDF] Poster pr\u00e9sent\u00e9 au SITC 2024\u00a0 Listen to Dr. Alessandro Riva\u2019s comments, Chairman &#038; CEO of Transgene (VOST) Liste to the KOL Event TG4050 (April, 2023)&hellip;\u2026","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/30451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=30451"}],"version-history":[{"count":2,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/30451\/revisions"}],"predecessor-version":[{"id":39609,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/30451\/revisions\/39609"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=30451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=30451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=30451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}